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2-(Aryl-sulfonyl)oxetanes as designer 3-dimensional
fragments for fragment screening: synthesis and
strategies for functionalisation†
Kate F. Morgan,a Ian A. Hollingsworthb and James A. Bull*a
2-Sulfonyl-oxetanes have been prepared, aﬀording non-planar struc-
tures with desirable physicochemical properties for fragment based
drug discovery. The oxetane motif was formed by an intramolecular
C–C bond formation. The fragments were further functionalised via
organometallic intermediates at the intact oxetane and aromatic rings.
Fragment based drug discovery (FBDD) is now a well-established
approach in the development of new drugs and lead compounds.1
Fragments provide desirable starting points for discovery chemistry
that allow increases in MW and lipophilicity during the optimisa-
tion of potency and selectivity,2,3 whilst remaining in drug-like
chemical space.4 The design of fragment libraries is a crucial
element to the success of screening. Although desirable criteria
for properties of fragments can vary by biological target, guidelines
for ‘fragment space’ proposed by Astex are widely cited (Rule-of-3:
MWo 300, c logPr 3, number of H-bond donors–acceptorsr3).5
It has recently been suggested that the incorporation of more
H-bond acceptors, up to 6, is advantageous in affording additional
binding elements and further points for derivatisation during
optimisation.6 Fragment screening samples a larger portion of
available chemical space and as such FBDD is also a promising
approach for complex and challenging targets such as protein–
protein interactions.7 Fragment libraries dominated by sp2 rich
molecules have been less successful in generating hits for these
targets, suggesting more ‘3-dimensional’ fragments are likely to be
required.8 Indeed, more sp3-rich molecules and aliphatic hetero-
cycles can offer improved levels of success through development,
relative to highly aromatic compounds.9,10
Oxetanes have recently been highlighted as desirable low mole-
cular weight motifs for drug discovery.11 Carreira, Rogers-Evans,
Mu¨ller, and coworkers have shown an oxetane motif can act as an
isosteric, polar replacement for a gem-dimethyl group or a carbonyl,
which can result in improved physicochemical and biochemical
properties relative to the parent molecule.12 Enhanced solubility,
reduced lipophilicity, reduced hERG liability as well as improved
metabolic stability were observed as potential beneficial eﬀects.
The oxetane motif is also found in several biologically active
natural products, such as oxetanocin, taxol and mitrophorone.13
As a result, oxetanes have recently received significant interest in
medicinal chemistry.14
We are interested in the preparation of novel non-planar
fragments, with desirable properties, which contain biologically
important motifs, and access new areas of chemical space.15
Consequently we designed 2-sulfonyl oxetanes (Fig. 1), as non-
planar fragments to comply with the rule-of-3, modified for the
number of hydrogen bond acceptors (HBA).16 We envisaged that
these small and functional group rich molecules, with the
potential to make interesting interactions, would be desirable
fragments for screening in drug discovery or chemical biology
programmes. In addition they would allow the structure to be
‘grown’ or ‘linked’ in several directions for optimisation, were
they to be a hit. Here we report the synthesis of sulfonyl oxetanes
as well as their further functionalization.
The synthesis of oxetanes remains a challenge. Methods for the
synthesis of oxetanes are mostly limited to two general approaches:
photochemical Paterno`–Bu¨chi [2+2] reactions of carbonyl com-
pounds with alkenes,17 or intramolecular Williamson etherification
(Fig. 2).11,18 Recently epoxide ring opening/ring closing has been
exploited as a facile route to the activated intermediate that
Fig. 1 Sulfonyl-oxetane targets. MW = molecular weight; c log P = calculated
logP (lipophilicity);‡ HAC = heavy atom count (number of non-H atoms); HBD/A =
number of hydrogen bond donors–acceptors.
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undergoes etherification.19 Substituted oxetanes have also been
generated from exo-methylene oxetanes.20 However, these appro-
aches are unsuitable for our targets, particularly due to the
instability of the often required a-sulfonyl oxy-anion intermediate.21
To incorporate the 2-sulfonyl group, we envisaged a strategy
involving C–C bond formation, as opposed to the usual C–O bond
formation (Fig. 2, lower). While this approach is necessitated in
ring closure to form cyclobutanes and is known in the synthesis of
azetidines,22 it has not been exploited for oxetane synthesis. For
oxetanes, a comparable mode of cyclisation has only been observed
in intramolecular epoxide opening of lithiated benzyl ethers, using
LDA-KOtBu at 78 1C.23,24
The route developed to sulfonyl-oxetanes 1a–d is shown in
Scheme 1. The cyclisation precursors were accessed by alkylation of
ethylene glycol with chloromethyl aryl-sulfide to afford S,O-acetal 3,
using ethylene glycol as solvent to avoid double alkylation. Tosylation25
followed by oxidation withmCPBA afforded sulfone 4. The crucial step,
the 4-exo-tet cyclisation, was optimised with 4a, varying reaction
temperature, time, base and equivalents, solvent and concentration.26
Excellent yields were obtained using LiHMDS (1.1 equiv.) at 0 1C in
THF. Under these conditions the reactionwas complete in 1 h, with the
carbenoid-like organolithium intermediate stable to decomposition.
Cyclisation did not occur at lower temperatures and a larger excess of
base led to decomposition of the product. The route could be readily
scaled and the cyclisationwas performed on 6.5mmol affording >1 g of
oxetane 1a in 93%yield. By thismethod the synthesis of oxetanes 1b–d,
were similarly successful, modifying the size and electronics of the
aromatic, including the incorporation of a pyridine ring.
An important part of our design was the ability to ‘grow’ the
fragments by subsequent C–C bond formation in various directions.
Therefore, having validated the route to the sulfonyl oxetanes we
focused on the functionalisation of this molecule as a way to access
a variety of fragment-like, and larger lead-like compounds. Sulfones
can facilitate a wide array of transformations and here we envisaged
they would allow functionalization of the intact oxetane ring by
metallation. Capriati and co-workers recently reported an efficient
route to 2-substituted phenyloxetanes via 2-lithio-2-phenyloxetane,
formed by deprotonation with sBuLi, which was reacted with
electrophiles.27 We envisaged that the sulfonyl oxetane would
undergo regioselective deprotonation on the oxetane ring and this
was examined first. We investigated several bases to successfully
perform this deprotonation and identified 2 sets of reaction condi-
tions that were appropriate for different electrophiles.26 The use of
LiHMDS (1.2 equiv.) at78 1C in THF afforded clean reactions with
compatible electrophiles (Table 1, conditions A). Under these con-
ditions methyl, ethyl and allyl groups were introduced in excellent
yield (entries 1, 3 and 4).16
A second set of conditions using nBuLi (Table 1, conditions B)
was more suitable for some electrophiles. These conditions were
successful using methyl iodide and 3-fluorobenzyl bromide
(entries 2 and 5). In addition, these conditions were successful
with iso-butyraldehyde, which was unsuccessful using the amide
base, to give oxetane 9 in high yield (entry 6).
Oxetane 5 was then derivatised at the aryl group by directed
ortho-metallation (Scheme 2). Snieckus has demonstrated
that tBu-aryl sulfones are powerful directing groups for ortho
metallation.28,29 Employing the Snieckus conditions using MeI
successfully aﬀorded ortho-methylated oxetane 10.
Finally we examined the cross-coupling of sulfonyl oxetane
1c from the aryl chloride. The chloride substituent provides an
Fig. 2 Approaches to 2-substituted oxetanes.
Scheme 1 Synthetic route to sulfonyl oxetanes 1a–d via C–C bond formation.
aReaction scale in parentheses: mmol of 4 employed.
Table 1 Lithiation of sulfonyl oxetane 1a and reaction with electrophiles
Entry Electrophile (E+) Conditionsa Oxetane Yield (%)
1 MeI A
5
93
2 MeI B 71
3 EtI A 6 85
4 Allyl bromide A 7 91
5 B 8 90
6 B 9 86b
a Conditions A: LiHMDS (1.2 equiv.), electrophile (2 equiv.) THF, 78 1C,
90min; conditions B: nBuLi (1.3 equiv.), electrophile (2 equiv.) THF,78 1C,
30 min. b Isolated as a mixture of diastereoisomers, d.r. = 1 : 0.9.
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interesting potential binding element and also provides a route
to further derivatisation to access alkyl and aryl derivatives.
Fu¨rstner recently reported an iron-catalysed cross-coupling of
Grignard reagents with aryl chlorides.30 Employing Fu¨rstner’s
conditions with 1c aﬀorded oxetanes 11 and 12 in good yields.
Hexylmagnesium bromide and propylmagnesium chloride
were successfully cross-coupled, in the presence of the acidic
a-sulfonyl oxetane proton, and without noticeable ring opening
of the oxetane (Scheme 3, conditions a).
Suzuki cross-couplings of chloride 1c with boronic acids were
also successful using Buchwald’s SPhos ligand with Pd-catalysis
(Scheme 3, b).31 Electron-rich and electron-poor aromatic boronic
acids were successful, aﬀording oxetanes 13–16.
In summary, here we report a new approach to the synthesis
of 2-functionalised oxetanes that provides novel fragment-like com-
pounds. The initial fragments can be further elaborated through
lithiation on the oxetane ring itself, by directed ortho-metallation on
the aromatic, as well as by iron and palladium catalysed cross-
couplings of the aryl chloride. We are currently expanding the
diversity of small ring fragments that can be obtained by this
approach and developing enantioselective routes.
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